Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-5914
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKonstantinides, Stavros-
dc.contributor.authorMeyer, Guy-
dc.date.accessioned2021-05-25T10:45:34Z-
dc.date.available2021-05-25T10:45:34Z-
dc.date.issued2020-
dc.identifier.urihttps://openscience.ub.uni-mainz.de/handle/20.500.12030/5923-
dc.description.abstractPulmonary embolism (PE) is the third most frequent acute cardiovascular syndrome. Annual PE incidence and PE-related mortality rates rise exponentially with age, and consequently, the disease burden imposed by PE on the society continues to rise as the population ages worldwide. Recently published landmark trials provided the basis for new or changed recommen- dations included in the 2019 update of the European Society of Cardiology Guidelines (developed in cooperation with the European Respiratory Society). Refinements in diagnostic algorithms were proposed and validated, increasing the specificity of pre-test clinical probability and d-dimer testing, and thus helping to avoid unnecessary pulmonary angiograms. Improved diagnostic strategies were also successfully tested in pregnant women with suspected PE. Non-vitamin K antagonist oral anticoagulants (NOACs) are now the preferred agents for treating the majority of patients with PE, both in the acute phase (with or without a brief lead-in period of parenteral heparin or fondaparinux) and over the long term. Primary reperfusion is reserved for haemodynamically unstable patients. Besides, the 2019 Guidelines endorse multidisciplinary teams for coor- dinating the acute-phase management of high-risk and (in selected cases) intermediate-risk PE. For normotensive patients, physicians are advised to include the assessment of the right ventricle on top of clinical severity scores in further risk strati- fication, especially if early discharge of the patient is envisaged. Further important updates include guidance (1) on extended anticoagulation after PE, taking into account the improved safety profile of NOACs; and (2) on the overall care and follow-up of patients who have suffered PE, with the aim to prevent, detect and treat late sequelae of venous thromboembolism.en_GB
dc.language.isoengde
dc.rightsCC BY*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subject.ddc610 Medizinde_DE
dc.subject.ddc610 Medical sciencesen_GB
dc.titleManagement of acute pulmonary embolism 2019 : what is new in the updated European guidelines?en_GB
dc.typeZeitschriftenaufsatzde
dc.identifier.doihttp://doi.org/10.25358/openscience-5914-
jgu.type.dinitypearticleen_GB
jgu.type.versionPublished versionde
jgu.type.resourceTextde
jgu.organisation.departmentFB 04 Medizinde
jgu.organisation.number2700-
jgu.organisation.nameJohannes Gutenberg-Universität Mainz-
jgu.rights.accessrightsopenAccess-
jgu.journal.titleInternal and emergency medicinede
jgu.journal.volume15de
jgu.pages.start957de
jgu.pages.end966de
jgu.publisher.year2020-
jgu.publisher.nameSpringer Milande
jgu.publisher.placeMilande
jgu.publisher.urihttps://doi.org/10.1007/s11739-020-02340-0de
jgu.publisher.issn1970-9366de
jgu.organisation.placeMainz-
jgu.subject.ddccode610de
jgu.publisher.doi10.1007/s11739-020-02340-0
jgu.organisation.rorhttps://ror.org/023b0x485
Appears in collections:JGU-Publikationen

Files in This Item:
  File Description SizeFormat
Thumbnail
konstantinides_stavros-management_of_-20210514091325366.pdf924.69 kBAdobe PDFView/Open